165 related articles for article (PubMed ID: 30042176)
1. Long-term Tumor Adaptation after Radiotherapy: Therapeutic Implications for Targeting Integrins in Prostate Cancer.
Eke I; Makinde AY; Aryankalayil MJ; Reedy JL; Citrin DE; Chopra S; Ahmed MM; Coleman CN
Mol Cancer Res; 2018 Dec; 16(12):1855-1864. PubMed ID: 30042176
[TBL] [Abstract][Full Text] [Related]
2. RAD9 enhances radioresistance of human prostate cancer cells through regulation of ITGB1 protein levels.
Broustas CG; Lieberman HB
Prostate; 2014 Oct; 74(14):1359-70. PubMed ID: 25111005
[TBL] [Abstract][Full Text] [Related]
3. β1 integrin- and JNK-dependent tumor growth upon hypofractionated radiation.
Sayeed A; Lu H; Liu Q; Deming D; Duffy A; McCue P; Dicker AP; Davis RJ; Gabrilovich D; Rodeck U; Altieri DC; Languino LR
Oncotarget; 2016 Aug; 7(33):52618-52630. PubMed ID: 27438371
[TBL] [Abstract][Full Text] [Related]
4. Suppression of ITGB4 Gene Expression in PC-3 Cells with Short Interfering RNA Induces Changes in the Expression of β-Integrins Associated with RGD-Receptors.
Knyazev EN; Nyushko KM; Alekseev BY; Samatov TR; Shkurnikov MY
Bull Exp Biol Med; 2015 Aug; 159(4):541-5. PubMed ID: 26395630
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model.
Inoue T; Anai S; Onishi S; Miyake M; Tanaka N; Hirayama A; Fujimoto K; Hirao Y
BMC Urol; 2013 Jan; 13():1. PubMed ID: 23289871
[TBL] [Abstract][Full Text] [Related]
6. Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.
Eke I; Makinde AY; Aryankalayil MJ; Sandfort V; Palayoor ST; Rath BH; Liotta L; Pierobon M; Petricoin EF; Brown MF; Stommel JM; Ahmed MM; Coleman CN
Mol Cancer Ther; 2018 Feb; 17(2):355-367. PubMed ID: 28802252
[TBL] [Abstract][Full Text] [Related]
7. The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo.
Gonnissen A; Isebaert S; McKee CM; Dok R; Haustermans K; Muschel RJ
Oncotarget; 2016 Dec; 7(51):84286-84298. PubMed ID: 27713179
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy.
Abdollahi A; Griggs DW; Zieher H; Roth A; Lipson KE; Saffrich R; Gröne HJ; Hallahan DE; Reisfeld RA; Debus J; Niethammer AG; Huber PE
Clin Cancer Res; 2005 Sep; 11(17):6270-9. PubMed ID: 16144931
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of CD146/MCAM Reduces Bone Metastasis in Prostate Cancer.
Zoni E; Astrologo L; Ng CKY; Piscuoglio S; Melsen J; Grosjean J; Klima I; Chen L; Snaar-Jagalska EB; Flanagan K; van der Pluijm G; Kloen P; Cecchini MG; Kruithof-de Julio M; Thalmann GN
Mol Cancer Res; 2019 May; 17(5):1049-1062. PubMed ID: 30745464
[TBL] [Abstract][Full Text] [Related]
10. β1 integrins mediate resistance to ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase 1.
Goel HL; Sayeed A; Breen M; Zarif MJ; Garlick DS; Leav I; Davis RJ; Fitzgerald TJ; Morrione A; Hsieh CC; Liu Q; Dicker AP; Altieri DC; Languino LR
J Cell Physiol; 2013 Jul; 228(7):1601-9. PubMed ID: 23359252
[TBL] [Abstract][Full Text] [Related]
11. Silibinin inhibits fibronectin induced motility, invasiveness and survival in human prostate carcinoma PC3 cells via targeting integrin signaling.
Deep G; Kumar R; Jain AK; Agarwal C; Agarwal R
Mutat Res; 2014 Oct; 768():35-46. PubMed ID: 25285031
[TBL] [Abstract][Full Text] [Related]
12. Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor.
Thomas F; Holly JM; Persad R; Bahl A; Perks CM
Prostate; 2010 Jun; 70(8):856-65. PubMed ID: 20127733
[TBL] [Abstract][Full Text] [Related]
13. MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation.
Moretti L; Niermann K; Schleicher S; Giacalone NJ; Varki V; Kim KW; Kopsombut P; Jung DK; Lu B
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1189-97. PubMed ID: 21514073
[TBL] [Abstract][Full Text] [Related]
14. Salicylate enhances the response of prostate cancer to radiotherapy.
Broadfield LA; Marcinko K; Tsakiridis E; Zacharidis PG; Villani L; Lally JSV; Menjolian G; Maharaj D; Mathurin T; Smoke M; Farrell T; Muti P; Steinberg GR; Tsakiridis T
Prostate; 2019 Apr; 79(5):489-497. PubMed ID: 30609074
[TBL] [Abstract][Full Text] [Related]
15. Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis.
Lee YC; Jin JK; Cheng CJ; Huang CF; Song JH; Huang M; Brown WS; Zhang S; Yu-Lee LY; Yeh ET; McIntyre BW; Logothetis CJ; Gallick GE; Lin SH
Mol Cancer Res; 2013 Apr; 11(4):405-17. PubMed ID: 23339185
[TBL] [Abstract][Full Text] [Related]
16. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
Arafat W; Zhou T; Naoum GE; Buchsbaum DJ
J Egypt Natl Canc Inst; 2015 Dec; 27(4):205-15. PubMed ID: 26385392
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
Brooks C; Sheu T; Bridges K; Mason K; Kuban D; Mathew P; Meyn R
Radiat Oncol; 2012 Sep; 7():154. PubMed ID: 22967802
[TBL] [Abstract][Full Text] [Related]
18. β4 Integrin signaling induces expansion of prostate tumor progenitors.
Yoshioka T; Otero J; Chen Y; Kim YM; Koutcher JA; Satagopan J; Reuter V; Carver B; de Stanchina E; Enomoto K; Greenberg NM; Scardino PT; Scher HI; Sawyers CL; Giancotti FG
J Clin Invest; 2013 Feb; 123(2):682-99. PubMed ID: 23348745
[TBL] [Abstract][Full Text] [Related]
19.
Kwon OY; Ryu S; Choi JK; Lee SH
Molecules; 2020 Jun; 25(13):. PubMed ID: 32630092
[No Abstract] [Full Text] [Related]
20. Epigenetic regulation of the ITGB4 gene in prostate cancer.
Wilkinson EJ; Woodworth AM; Parker M; Phillips JL; Malley RC; Dickinson JL; Holloway AF
Exp Cell Res; 2020 Jul; 392(2):112055. PubMed ID: 32376286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
